title: Effects of A1 adenosine receptor agonism using N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular dysfunction.
abstract: BACKGROUND
  The role of adenosine as a neuromodulator in heart failure was studied with the use of a selective adenosine A1 receptor agonist, N6-cyclohexyl-2'-O-methyladenosine (SDZ-WAG 994).
  
  
  RESULTS
  Fifty patients with heart failure symptoms and moderate left ventricular systolic dysfunction had a balloon flotation catheter inserted. Patients received placebo or a single oral dose of either 1, 2, or 5 mg SDZ-WAG 994. After baseline measurements were obtained, hemodynamic and electrophysiological recordings were repeated at 30-minute intervals for the next 4 hours, then every 6 hours for the next 24 hours. Blood samples for norepinephrine, epinephrine, aldosterone, atrial natriuretic peptide, and plasma renin activity were drawn at baseline and 2 hours after drug administration. A adenosine receptor agonism produced no important effects on systemic, right atrial, pulmonary artery, or pulmonary capillary wedge pressures; cardiac index; respiratory rate; or heart rate. The PR interval (a reflection of A1 receptor-mediated activity) increased significantly in a stepwise fashion. At the 5-mg dose of SDZ-WAG 994, significant increases in atrial natriuretic peptide (216 +/- 137 to 407 +/- 146 pg/mL) and norepinephrine (477 +/- 243 to 618 +/- 237 pg/mL) levels were noted.
  
  
  CONCLUSIONS
  A1 adenosine receptor agonism with SDZ-WAG 994 resulted in no significant hemodynamic changes at rest in this subset of patients with left ventricular dysfunction. An increase in the PR interval and atrial natriuretic peptide level, consistent with adenosine A1 receptor-mediated activity, was observed. In addition, an increase in the norepinephrine level was observed, suggesting a role for adenosine as a peripheral nervous system neuromodulator.
authors.affiliation: Department of Medicine, University of Florida Health Sciences Center, Gainesville 32610-0277, USA.
authors.forename: B D
authors.initials: BD
authors.lastname: Bertolet
authors.forename: I S
authors.initials: IS
authors.lastname: Anand
authors.forename: R J
authors.initials: RJ
authors.lastname: Bryg
authors.forename: P K
authors.initials: PK
authors.lastname: Mohanty
authors.forename: K
authors.initials: K
authors.lastname: Chatterjee
authors.forename: J N
authors.initials: JN
authors.lastname: Cohn
authors.forename: N S
authors.initials: NS
authors.lastname: Khurmi
authors.forename: C J
authors.initials: CJ
authors.lastname: Pepine
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D004562:Electrocardiography; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006728:Hormones / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D058906:Purinergic P1 Receptor Agonists; D018047:Receptors, Purinergic P1 / Q000502:physiology; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D006728:Hormones; D058906:Purinergic P1 Receptor Agonists; D018047:Receptors, Purinergic P1; C090949:N(6)-cyclohexyl-2-O-methyladenosine; D000241:Adenosine